BS - Bone, Cartilage, Molecular Biology, &c Flashcards
Signal through tyrosine kinase receptors
Fibroblast growth factors, insulin-like growth factors, and platelet-derived growth factors
Parathyroid hormone receptor SIGNALLING MECHANISM
adenylyl cyclase/G-alpha stimulatory protein/cAMP/protein kinase A
TGF-ß SIGNALLING AND EFFECT osteoblasts
stimulates osteoblasts to synthesize collagen and primarily signal through serine/threonine kinase receptors
BMP SIGNALLING MECHANISM
BMPs target undifferentiated mesenchymal cells and signal through serine/threonine kinase receptors
SMADS are primary intracellular signaling mediator for bone morphogenetic protein
IGF-II SIGNALLING MECHANISM
tyrosine kinase receptors
Osteoclast ACTIVATING MOLECULES (7)
RANKL, PTH, IL1, 1,25 Vitamin D
prostaglandin E2, IL-6, MIP-1A
Osteoclast INHIBITING MOLECULES (6)
OPG, calcitonin (osteoclast receptor), estrogen, TGFbeta, IL-10
DENOSUMAB (monoclonal ab binds to RANKL like OPG)
Type 1 collagen breakdown marker
hydroxy-proline
BMP3 features (3)
Antagonizes BMP2
Most abundant BMP in demineralized bone matrix
increases chondrogenic markers
Factor that couples bone resorption and formation
TGFß
- signals osteoblasts to make bone
- acid pH activates TGFß family
- negative effect on epithelial cell proliferation
TGFß signalling pathway
Type I/II receptor –> SMAD4
- SMURFS regulate and breakdown SMADs
TGFß effects on cartilage
chondrocyte hypertrophy
(TGFß knockout mice –> arthritis)
Name 2 adhesive proteins and their function
Fibronectin - osteoblast adhesion to bone and survival
Vitronectin - osteoclast adhesion to bone (alpha-v/neta-3 integrin receptor)
Osteoblast markers (5)
osteocalcin (most specific)
alk phos
PTH receptor
osteonectin
osteopontin
osteoclast markers (4)
TRAP (tartrate resistant acid phosphatase)
calcitonin receptor
RANK
alpha-v/beta-e integrin receptor
LRP5 signalling pathway and effects
Wnt/Frizzled transduction pathway
regulates osteoblast activity
Loss function = poor bone mass “osteoporosis-pseudoglioma”
Gain function - very high boner mass
osteoporosis features (3)
- T score < 2.5 std dev (below peak bone mass)
- normal mineralization
- abnormal microarchitecture (anisotropy increased, porosity increased)
Contraindications PTH therapy (4)
- Paget’s/post irradiation (risk for osteosarc)
- open physes
- hyperparathyroidism
- metastatic bone disease
Trabecular bone features (3)
- maximum thickness plates and rods 200 micron
- blood supply = diffusion
- 30-90% porosity
Hydroxyapatite molecular formula
Ca10(PO4)6(OH)2
- Stone man syndrome, aka “fibrodysplasia ossificans progressiva”
- activating mutation in ACVR1 (BMP receptor)
Schwartzman’s reaction
systemic response to bacterial endotoxins –> DIC, fat embolism, thrombosis
May cause OSTEONECROSIS
Names and mechanism of nitrogen containing bisphosphonates
alendronate, risedronate, pamidronate, zolendronate
- inhibit mevalonate (cholesterol pathway)
- inhibits osteoclast farnesyl pyrophosphate synthase enzyme
-prevent post-translational prenylation of GTP-binding proteins
- inhibits ruffled border and microtubules
Names and mechanism of NON-nitrogen containing bisphosphonates
tiludronate, clodronate, etidronate
- produce toxic analogs of ATP
Bisphosponate indications (7)
osteogenesis imperfecta
osteoporosis
metastatic bone disease
multiple myeloma
paget’s disease
polyostotic fibrous dysplasia
early stage avascular necrosis (precollapse)
bisphosphonate contraindications (2)
severe renal disease
following lumbar fusion